AngioSafe delivers a single-step, wire-free intraplaque crossing solution that modifies plaque and prepares the vessel for further treatment – all in one smooth move. The company is pioneering Atheroplasty™, a new era in endovascular revascularization designed to treat severely or totally occluded arteries with minimal risk of complications.
Founded to flip the script in revascularization, AngioSafe empowers physicians to treat complex interventions in peripheral and coronary arterial diseases (PAD and CAD) more safely, faster, and with greater predictability. Its technology replaces multiple device families, simplifying procedures for chronic total occlusions (CTOs).
AngioSafe is the first philanthropically funded medical device company, with investors committed to donating a portion of returns to global not-for-profit organizations.
